news

Receptor identified as potential target for treatment of autism

Posted: 1 October 2015 | Victoria White

Scientists have uncovered a relationship between a chemical that helps transmit signals in the brain and genetic mutations present in a subset of individuals with autism…

Scientists from The Scripps Research Institute (TSRI) have uncovered a significant – and potentially treatable – relationship between a chemical that helps transmit signals in the brain and genetic mutations present in a subset of individuals with autism spectrum disorder.

The new research findings focus on the role that the neurotransmitter serotonin plays in the development of social behaviour. Serotonin, together with the serotonin receptors it activates in the brain, plays a significant role in neurological processes, including mood, anxiety, aggression and memory.

The study made use of an animal model of mutations in the gene Pten, a risk factor present in a subgroup of individuals with autism. Treatment of this model with a drug that suppresses the activity of a particular serotonin receptor, 5-HT2cR, can have a dramatic effect.

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

Discovery could lead to new therapeutic strategies for autism

“Our research shows that targeting one specific serotonin receptor can reverse social deficits in a mouse model of the autism risk gene Pten,” said Julien Séjourné. “This discovery is important for understanding the role of this specific subtype of serotonin receptor in autism-relevant behaviours and could lead to new therapeutic strategies.”

“We found a striking contrast between the effects of dialling down the activity of the receptor using a drug, which improved social deficits in the Pten model, versus removing the receptor completely by mutation, which actually impaired social behaviour,” added TSRI Assistant Professor Damon Page, who led the study. “Important issues will be uncovering the mechanism by which modulating serotonin receptor activity can influence autism-relevant symptoms and identifying the time window and dose range where targeting serotonin receptors is most effective.”

Page was recently awarded a $2.4 million grant from the US National Institutes of Health (NIH) to further study the relationship between abnormal patterns of brain growth, neurotransmitter signalling and the behavioural and cognitive symptoms in individuals with autism spectrum disorder.

“The new grant will let us expand our research into the relationship between specific risk factors, altered brain development and key neurotransmitter systems, with the ultimate goal of moving toward individualised treatments for particular subgroups of individuals with autism spectrum disorder,” he said.

Related topics